Partnering is key to our corporate strategy. iTeos is actively seeking collaboration and licensing opportunities in cancer immunotherapy. iTeos’ formation and growth has benefited from strategic partnerships and licensing that have expanded our tumor immunology expertise and technology, and contributed to our pipeline.

For partnering enquiries, please contact us at